English | 简体中文 | 繁體中文 | 한국어
Share:
NEOVACS ANNOUNCES THE CONTINUATION OF THE DEVELOPMENT OF ITS IFNalpha KINOID IN SOUTH KOREA WITH ITS PARTNER CHONG KUN DANG (CKD) PHARMACEUTICALS

PRESS RELEASE · PRESS RELEASE · PRESS RELEASE

NEOVACS ANNOUNCES THE CONTINUATION OF THE DEVELOPMENT OF ITS IFNalpha KINOID IN SOUTH KOREA WITH ITS PARTNER CHONG KUN DANG (CKD) PHARMACEUTICALS

Both partners have agreed to prepare the filing for an Orphan Drug Designation (ODD)

Paris and Boston, the 11th of October 2018 - 07:00 AM CEST- Neovacs (Euronext Growth Paris ALNEV), leader in active immunotherapy for the treatment of auto-immune diseases, today announces the continuation of the development of its IFNalpha Kinoid in South Korea with its partner Chong Kun Dang (CKD) Pharmaceutical Corp, on the basis of the licensing agreement signed in December 2015, for a potential overall value of 5M€. This agreement covers the development and the commercialization of IFNalpha Kinoid in South Korea for Lupus and Dermatomyositis indications.

Within this agreement both partners have agreed to prepare the filing for an "ODD" in South Korea, based on the results of the Phase IIb trial in Lupus with IFNalpha Kinoid.

Neovacs had already received in 2016 an "Investigational New Drug" (IND) of South Korean Health authorities to include 5 investigational centers in its global Phase IIb trial for IFNalpha Kinoid. Neovacs was able therefore to gain the support of Korean Opinion Leaders in Lupus for its innovative therapeutic approach and to include Korean patients in the study.

« We are pleased with these results which represent a major progress in the research of a treatment for Lupus and the time is approaching when we will be able to offer a satisfying treatment to patients. We are satisfied to continue this partnership and will now make our best efforts to accelerate the development of IFNalpha Kinoid in South Korea within the specific status of this indication in the Korean legislation » declares Young Joo Kim, President of CKD»

« We are delighted that our Korean partner shares our appraisal of the trial results and are confident for the future development of IFNalpha Kinoid in South Korea » concludes Miguel Sieler, CEO of Neovacs.

Neovacs will receive potentially up to 5 million euros in total under this license agreement in sequenced payments, based on the achievement of certain milestones, which include the Phase IIb results.

About Chong Kun Dang Pharmaceutical Corp.
Founded in 1941, CKD is a fully integrated pharmaceutical company employing over 2,000 people. It is one of the leading local pharma companies in Korea and through in-licensing and in-house R&D, it has significantly contributed to improving health and quality of life of people mainly in Korea for more than 70 years. Domestically, it has a strong presence in cardiovascular and immunosuppressant areas and has local offices established in Vietnam and Indonesia. As a leading pharma in Immunosuppressants in Korea, CKD continues to strengthen its major therapeutic area by its R&D capability and licensing-in innovative drugs from business partners worldwide. http://www.ckdpharm.com/eng/company

About Neovacs
Listed on Euronext Growth since 2010, Neovacs is today a leading biotechnology company focused on an active immunotherapy technology platform (Kinoids) with applications in autoimmune and/or inflammatory diseases. On the basis of the company's proprietary technology for inducing a polyclonal immune response (covered by four patent families that potentially run until 2032) Neovacs is focusing its clinical development efforts on IFNalpha Kinoid, an immunotherapy being developed for the indication of lupus, dermatomyositis and also in preclinical trial for Type 1 diabetes. Neovacs is also conducting preclinical development works on other therapeutic vaccines in the fields of auto-immune diseases, oncology and allergies. The goal of the Kinoid approach is to enable patients to have access to safe treatments with efficacy that is sustained in these life-long diseases. www.neovacs.fr

Contacts

NEOVACS - Corporate Communication & Investor Relations
Charlène Masson
+33 1 53 10 93 00
[email protected]




This announcement is distributed by West Corporation on behalf of West Corporation clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: NEOVACS via Globenewswire

Copyright © Thomson Reuters 2018. All rights reserved.
Press Releases
SeaBird Exploration: SeaBird received extension to current OBN survey in US Gulf of Mexico  
Oct 15, 2018 09:00 ET
Klövern AB (publ): Klövern considers issue of hybrid bonds  
Oct 15, 2018 08:30 ET
Amer Sports third quarter 2018 results published on October 25  
Oct 15, 2018 08:00 ET
ABN AMRO press release: Pre-closing announcements  
Oct 15, 2018 08:00 ET
Roche launches NGS AVENIO Tumor Tissue Analysis Kits for oncology research  
Oct 15, 2018 07:05 ET
INGREDION TO RELEASE 2018 THIRD-QUARTER FINANCIAL RESULTS AND HOLD CONFERENCE CALL AND WEBCAST ON THURSDAY, NOVEMBER 1, 2018  
Oct 11, 2018 22:29 ET
Eastman Schedules Third-Quarter 2018 Financial Results News Release and SEC Form 8-K Filing, Teleconference and Webcast  
Oct 4, 2018 22:29 ET
JCPenney Launches Peyton and Parker,(TM) a New Private Brand Designed for Families and Socially Connected Moms  
Oct 2, 2018 22:29 ET
Lubrizol and Danquinsa Feature High-Performing Bonding Solutions and Non-Yellowing TPUs at Fakuma 2018  
Sept 26, 2018 21:59 ET
INGREDION ANNOUNCES $60 MILLION OF INCREMENTAL PLANNED SPECIALTY CAPITAL INVESTMENTS IN ASIA-PACIFIC; Company's latest move expands its capacity for higher-value specialty ingredients  
Sept 26, 2018 21:29 ET
More News >>
Copyright © 2018 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 800 291 0906 | Beijing: +86 10 8405 3688 | Hong Kong: +852 2217 2912 | Singapore: +65 6304 8926 | Tokyo: +81 3 5791 1818

Connect With us: